Fibromyalgia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The global Fibromyalgia Treatment Market is witnessing substantial growth, with total revenues reaching US$ 1.5 billion in 2024. The market to an estimated valuation of approximately US$ 2.5 billion by the end of 2031.

Regional Dynamics

North America is anticipated to dominate the market during the forecast period, primarily due to the high prevalence of fibromyalgia in the region and the availability of advanced treatment options. However, the Asia Pacific region is poised for the fastest CAGR, driven by increasing awareness of fibromyalgia and growing demand for effective treatments.

Segmentation

The fibromyalgia treatment market is categorized based on treatment type into pharmaceutical treatments and non-pharmaceutical treatments. Pharmaceutical treatments include antidepressants, anticonvulsants, muscle relaxants, and analgesics, while non-pharmaceutical treatments encompass physical therapy, cognitive-behavioral therapy (CBT), and other therapies such as acupuncture and massage therapy.

Understanding Fibromyalgia

Fibromyalgia (FM) is characterized by widespread, chronic musculoskeletal pain, significantly impacting a patient's quality of life. It often coexists with other functional disorders like depression, chronic fatigue syndrome, and anxiety. FM is considered a condition of central sensitization, affecting individuals worldwide with a prevalence ranging from 2% to 4% in general populations.

Challenges in FM Treatment

Fibromyalgia presents a unique set of challenges as none of the available treatments offer complete relief from its symptoms, including pain, exhaustion, sleep disturbances, and depression. Moreover, treatment compliance can be poor, leading to suboptimal outcomes.

Market Growth Drivers

Investigation of Novel Drugs and Combination Therapy: Pharmaceutical companies are investing in research and development to discover new therapies for fibromyalgia. This includes exploring new experimental drugs, combinations of existing drugs, and repurposing drugs used for other conditions. The aim is to enhance the quality of life for FM patients by addressing central and peripheral nervous system involvement.

Market Challenges

Lack of Approved Medications and Therapeutic Efficacy: Limited approved medications for FM treatment and the often ineffective nature of available therapies pose challenges. Additionally, the lack of reimbursements and high treatment costs impact patient access.

Booming U.S. Market

The United States is expected to lead the global fibromyalgia treatment market due to its substantial consumer base, recent product launches, and the presence of leading manufacturers.

Lucrative Market in Germany

Germany's market is projected to grow due to the absence of approved fibromyalgia treatment options and the introduction of new products.

China's Emergence in the Market

China is emerging as a prominent player in the fibromyalgia treatment market, driven by an aging population, increasing rates of rheumatic diseases, rising public awareness, and a surge in traumatic stress disorder and traffic accidents.

Competitive Landscape

The global fibromyalgia treatment market features both established and emerging market players actively investing in research and development to create innovative therapies. This has resulted in a robust pipeline of potential products advancing in clinical trials.

Key Companies Covered:

Pfizer, Inc.
Eli Lilly and Company
AbbVie, Inc.
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson Services, Inc
Sanofi
GlaxoSmithKline plc.
Bayer AG
TONIX Pharmaceuticals Holdings Corp
Virios Therapeutics, Inc.
Aptinyx Inc.
FSD Pharma

Market Segmentation

Drug Class:

Antidepressants

Venlafaxine

Duloxetine HCl

Milnacipran HCl

Others

Anticonvulsants

Pregabalin

Gabapentin

Others

Muscle Relaxants
Analgesics

Distribution Channel:

Hospitals Pharmacies
Drug Stores
Retail Pharmacies
Online Pharmacies

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Fibromyalgia Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Fibromyalgia Treatment Market Outlook, 2018 - 2031

3.1. Global Fibromyalgia Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Antidepressants
    - 3.1.1.1.1. Venlafaxine
    - 3.1.1.1.2. Duloxetine HCl
    - 3.1.1.1.3. Milnacipran HCl
    - 3.1.1.1.4. Others
  - 3.1.1.2. Anticonvulsants
    - 3.1.1.2.1. Pregabalin
    - 3.1.1.2.2. Gabapentin
    - 3.1.1.2.3. Others
  - 3.1.1.3. Muscle Relaxants
  - 3.1.1.4. Analgesics
3.2. Global Fibromyalgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Hospitals Pharmacies
  - 3.2.1.2. Drug Stores
  - 3.2.1.3. Retail Pharmacies
  - 3.2.1.4. Online Pharmacies
3.3. Global Fibromyalgia Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Fibromyalgia Treatment Market Outlook, 2018 - 2031

4.1. North America Fibromyalgia Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Antidepressants
    - 4.1.1.1.1. Venlafaxine
    - 4.1.1.1.2. Duloxetine HCl
    - 4.1.1.1.3. Milnacipran HCl
    - 4.1.1.1.4. Others
  - 4.1.1.2. Anticonvulsants
    - 4.1.1.2.1. Pregabalin
    - 4.1.1.2.2. Gabapentin
    - 4.1.1.2.3. Others
  - 4.1.1.3. Muscle Relaxants
  - 4.1.1.4. Analgesics
4.2. North America Fibromyalgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Hospitals Pharmacies
  - 4.2.1.2. Drug Stores
  - 4.2.1.3. Retail Pharmacies
  - 4.2.1.4. Online Pharmacies
- 4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Fibromyalgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Fibromyalgia Treatment Market Outlook, 2018 - 2031

5.1. Europe Fibromyalgia Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Antidepressants
    - 5.1.1.1.1. Venlafaxine
    - 5.1.1.1.2. Duloxetine HCl
    - 5.1.1.1.3. Milnacipran HCl
    - 5.1.1.1.4. Others
  - 5.1.1.2. Anticonvulsants
    - 5.1.1.2.1. Pregabalin
    - 5.1.1.2.2. Gabapentin
    - 5.1.1.2.3. Others
  - 5.1.1.3. Muscle Relaxants
  - 5.1.1.4. Analgesics
5.2. Europe Fibromyalgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Hospitals Pharmacies
  - 5.2.1.2. Drug Stores
  - 5.2.1.3. Retail Pharmacies
  - 5.2.1.4. Online Pharmacies
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Fibromyalgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.8. Italy Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.9. Turkey Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Fibromyalgia Treatment Market Outlook, 2018 - 2031

6.1. Asia Pacific Fibromyalgia Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Antidepressants
    - 6.1.1.1.1. Venlafaxine
    - 6.1.1.1.2. Duloxetine HCl
    - 6.1.1.1.3. Milnacipran HCl
    - 6.1.1.1.4. Others
  - 6.1.1.2. Anticonvulsants
    - 6.1.1.2.1. Pregabalin
    - 6.1.1.2.2. Gabapentin
    - 6.1.1.2.3. Others
  - 6.1.1.3. Muscle Relaxants
  - 6.1.1.4. Analgesics
6.2. Asia Pacific Fibromyalgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Hospitals Pharmacies
  - 6.2.1.2. Drug Stores
  - 6.2.1.3. Retail Pharmacies
  - 6.2.1.4. Online Pharmacies
- 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Fibromyalgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.3.1.2. China Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Fibromyalgia Treatment Market Outlook, 2018 - 2031

7.1. Latin America Fibromyalgia Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Antidepressants
    - 7.1.1.1.1. Venlafaxine
    - 7.1.1.1.2. Duloxetine HCl
    - 7.1.1.1.3. Milnacipran HCl
    - 7.1.1.1.4. Others
  - 7.1.1.2. Anticonvulsants
    - 7.1.1.2.1. Pregabalin
    - 7.1.1.2.2. Gabapentin
    - 7.1.1.2.3. Others
  - 7.1.1.3. Muscle Relaxants
  - 7.1.1.4. Analgesics
7.2. Latin America Fibromyalgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Hospitals Pharmacies
  - 7.2.1.2. Drug Stores
  - 7.2.1.3. Retail Pharmacies
  - 7.2.1.4. Online Pharmacies
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Fibromyalgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Fibromyalgia Treatment Market Outlook, 2018 - 2031

8.1. Middle East & Africa Fibromyalgia Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Antidepressants
    - 8.1.1.1.1. Venlafaxine
    - 8.1.1.1.2. Duloxetine HCl
    - 8.1.1.1.3. Milnacipran HCl
    - 8.1.1.1.4. Others
  - 8.1.1.2. Anticonvulsants
    - 8.1.1.2.1. Pregabalin
    - 8.1.1.2.2. Gabapentin
    - 8.1.1.2.3. Others
  - 8.1.1.3. Muscle Relaxants
  - 8.1.1.4. Analgesics
8.2. Middle East & Africa Fibromyalgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Hospitals Pharmacies
  - 8.2.1.2. Drug Stores
  - 8.2.1.3. Retail Pharmacies
  - 8.2.1.4. Online Pharmacies
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Fibromyalgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Manufacturer vs by Distribution Channel Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Pfizer, Inc
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Eli Lilly and Company
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. AbbVie, Inc.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Teva Pharmaceutical Industries Ltd.
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Johnson & Johnson Services, Inc
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Sanofi
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. GlaxoSmithKline plc.
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Bayer AG
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. TONIX Pharmaceuticals Holdings Corp
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Virios Therapeutics, Inc.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. Aptinyx Inc.
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development
- 9.4.12. FSD Pharma
  - 9.4.12.1. Company Overview
  - 9.4.12.2. Product Portfolio
  - 9.4.12.3. Financial Overview
  - 9.4.12.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations